Susquehanna International Group, LLP Leap Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 16, 2023	SELL	$0.29 - $0.72 $4,449 - $11,047	-15,344 Reduced 50.61%	14,973 $5,000
Q4 2022 Feb 14, 2023	SELL	$0.42 - $9.18 $4,837 - $105,744	-11,519 Reduced 27.53%	30,317 $13,000
Q3 2022 Nov 14, 2022	SELL	$0.92 - $9.3 $29,176 - $294,940	-31,714 Reduced 43.12%	41,836 $37,000
Q2 2022 Aug 15, 2022	SELL	$0.96 - $1.91 $50,448 - $100,370	-52,550 Reduced 41.67%	73,550 $85,000
Q1 2022 May 16, 2022	SELL	$1.6 - $3.35 $42,497 - $88,979	-26,561 Reduced 17.4%	126,100 $221,000
Q4 2021 Feb 14, 2022	BUY	$2.08 - $3.65 $317,534 - $557,212	152,661 New	152,661 $495,000
Q2 2020 Aug 14, 2020	SELL	$1.39 - $2.84 $39,959 - $81,644	-28,748 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.06 - $2.94 $12,986 - $36,017	12,251 Added 74.26%	28,748 $45,000
Q4 2019 Feb 14, 2020	BUY	$0.63 - $1.37 $10,393 - $22,600	16,497 New	16,497 $18,000
Q1 2018 May 15, 2018	SELL	$6.06 - $8.54 $316,525 - $446,061	-52,232 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$4.99 - $7.3 $260,637 - $381,293	52,232	52,232 $326,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $344M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.